Envisioning the Future of Analytical Development for Gene Therapies

by Megan Pease | February 16, 2022

Robotic Arm -Virus-extended-1141367276-2000x1200

As therapeutic approaches evolve, the testing and characterization methods for viral vector manufacturing need innovation to support these increasingly complex modalities. Like traditional therapeutics, testing is used to confirm product identity, purity, potency, and safety.

Differences in viral vector manufacturing require new approaches to testing and characterization. The shelf-life and quantity of material produced in one batch is limited compared to traditional biologics. By utilizing molecular-based methods of testing instead of traditional culture-based methods, the time to result and volume required for testing can be greatly reduced. Identifying relevant quality attributes and proper assay controls is necessary to confirm product identity.

Innovative analytical approaches to viral vector processing will consider risk in both raw materials and manufacturing methods. Utilizing quality by design approaches throughout the development process and leveraging templated manufacturing processes will help to implement and define assays for testing prior to the validation process. Aiming for a defined, templated manufacturing process with platform assays can streamline the production process, and ultimately ensure safe and well-characterized products for patients.

Read the full article: “Envisioning the Future of Analytical Development for Gene Therapies

[starbox id=”MeganPease”]

[molongui_author_box]

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

GEN Regulatory Podcast link LIVE!

The success of cell and gene therapy products in recent years to treat a host of complex diseases…

Assembling a new gene therapy company to develop the next generation of pioneering medicines

Having both recently graduated from our Masters degrees, Christina in Neuroscience from ETH Zürich and Charlotte in Chemistry…

Webinar: Developing A Scalable Upstream Bioreactor Process for Lentiviral Vector Production in Suspension

Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure…

Scroll to Top